rifampin has been researched along with quinupristin* in 5 studies
5 other study(ies) available for rifampin and quinupristin
Article | Year |
---|---|
Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2.
Topics: Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Evaluation, Preclinical; Drug Synergism; Humans; Molecular Conformation; Pandemics; Phylogeny; Pneumonia, Viral; Rifampin; RNA-Dependent RNA Polymerase; SARS-CoV-2; Sequence Alignment; Sequence Analysis, Protein; Virginiamycin; Virus Replication | 2020 |
[Persistent bacteremia caused by methicillin-resistant Staphylococcus aureus].
Topics: Aged; Bacteremia; Catheterization, Central Venous; Chronic Disease; Daptomycin; Discitis; Humans; Jugular Veins; Male; Methicillin-Resistant Staphylococcus aureus; Pancreatitis; Rifampin; Staphylococcal Infections; Vancomycin; Virginiamycin | 2008 |
In-vitro activity of quinupristin/dalfopristin, levofloxacin and moxifloxacin against fusidic acid and rifampicin-resistant strains of methicillin-resistant Staphylococcus aureus (MRSA) from Malaysian hospitals.
The in-vitro susceptibility of quinupristin/dalfopristin, levofloxacin and moxifloxacin against methicillin-resistant Staphylococcus aureus (MRSA) strains, which are also resistant to fusidic acid and rifampicin were carried out to determine whether these antibiotics can be used as an alternative treatment for multiply resistant MRSA strains. The minimum inhibitory concentrations (MIC) of these antibiotics were determined by E-test. Quinupristin/dalfopristin had good activity (MIC90 = 1 mg/L) against these strains while most of the strains showed intermediate resistance to moxifloxacin with MIC90 = 2 mg/L). However, more than 90% of these strains were resistant to levofloxacin with the MICs that ranged from 8 mg/L to 16 mg/L with the majority inhibited at 8 mg/L. Topics: Anti-Bacterial Agents; Aza Compounds; Disease Susceptibility; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Fusidic Acid; Humans; In Vitro Techniques; Levofloxacin; Malaysia; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Rifampin; Staphylococcus aureus; Virginiamycin | 2005 |
Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection.
We compared the efficacies of quinupristin-dalfopristin (Q-D; 30 mg/kg of body weight every 8 h) and vancomycin (60 mg/kg twice daily), alone or in combination with rifampin (10 mg/kg twice daily), in a rabbit model of methicillin-resistant Staphylococcus aureus knee prosthesis infection. In contrast to vancomycin, Q-D significantly reduced the mean log(10) CFU per gram of bone versus that for the controls. The combination of rifampin with either Q-D or vancomycin was significantly more effective than monotherapy. Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Drug Synergism; Drug Therapy, Combination; Joint Prosthesis; Methicillin Resistance; Prosthesis-Related Infections; Rabbits; Rifampin; Staphylococcal Infections; Tissue Distribution; Vancomycin; Virginiamycin | 2002 |
Antibiotic resistance rates and macrolide resistance phenotypes of viridans group streptococci from the oropharynx of healthy Greek children.
A total of 200 isolates of viridans group streptococci isolated from the oropharynx of healthy Greek children were studied. Vancomycin, rifampicin, fluoroquinolones and dalfopristin/quinupristin were active against all tested isolates. High level resistance to gentamicin was not seen. Intermediate and high-level penicillin resistance was present in 28.5 and 14.5% isolates, respectively, with 41.3% of the latter group, being also resistant to cefotaxime. Resistance rates to other antimicrobials were as follows - erythromycin 38.5%, clarithromycin 33.5%, clindamycin 7.5% and tetracycline 23%. Penicillin resistance occurred more frequently in Streptococcus mitis isolates, while macrolide resistance was more frequent in S. oralis. MLSB resistance phenotype M was dominant (74%) among erythromycin resistant isolates, with phenotypes IR and CR being represented by 6 and 20% of isolates, respectively. Topics: Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Child; Child, Preschool; Clarithromycin; Clindamycin; Drug Resistance, Microbial; Erythromycin; Female; Fluoroquinolones; Greece; Humans; Infant; Male; Microbial Sensitivity Tests; Oropharynx; Phenotype; Rifampin; Streptococcus; Tetracycline; Vancomycin; Virginiamycin | 2001 |